Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620410 | 0.87 | PDE5A (0.60) | PDE5AKMT2AKDM4ERXFP1CYP3A4 | |
| SCHEMBL2403854 | 0.85 | PDE5A (0.68) | PDE5AKMT2AKDM4ERXFP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL6446244 | 0.84 | PDE5A (0.67) | PDE5AKMT2AKDM4ERXFP1CYP3A4 | |
| SCHEMBL6447757 | 0.83 | PDE5A (0.56) | PDE5AKMT2AKDM4ERXFP1ALDH1A1 | |
| SCHEMBL6447306 | 0.81 | PDE5A (0.58) | PDE5AKMT2AKDM4ERXFP1ALDH1A1 | |
| SCHEMBL6446603 | 0.80 | PDE5A (0.53) | PDE5AKMT2AKDM4ERXFP1ALDH1A1 | |
| SCHEMBL3583879 | 0.80 | PDE5A (0.60) | PDE5AKMT2AKDM4ERXFP1ALDH1A1 | |
| SCHEMBL6445731 | 0.80 | PDE5A (0.49) | PDE5AKMT2AALDH1A1 | |
| SCHEMBL6442012 | 0.78 | PDE5A (0.70) | PDE5AKMT2AKDM4ERXFP1 | |
| SCHEMBL6446639 | 0.77 | PDE5A (0.49) | PDE5AKMT2AKDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885KMT2A 4533/4885KDM4E 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.